Logo

Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Share this
Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Incyte Enters into a Supply Agreement with Specialised Therapeutics to Launch Tafasitamab and Pemigatinib in Australia and Other Countries

Shots:

  • Incyte will lead the development- manufacture- and supply of both products. ST will be responsible for the regulatory- distribution- and local marketing related activities in Australia- New Zealand & Singapore
  • Tafasitamab + lenalidomide is approved in the US & EU to treat adult patients with r/r DLBCL who are not eligible for ASCT
  • Pemigatinib is approved in the US- EU & Japan to treat LA or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after one prior line of systemic therapy. In Jan'20- Incyte has entered into a collaboration and license agreement with MorphoSys to develop and commercialize tafasitamab globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: ECIJA


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family